News
01.24.23

OSRX® Names New Chief Formulation Officer

Brian Holdorf earns third promotion in five years at Montana-based ophthalmic compounding pharmacy

Brian Holdorf, a long-time compounding pharmacist who joined OSRX® – an affiliate of Ocular Science® – when it was formed in 2019, has ascended the corporate ladder while helping OSRX transform into a PCAB-accredited 503A compounding pharmacy that today produces customized ophthalmic formulations for physicians and their patients across the country.

Earlier this month, Holdorf received his third promotion in five-plus years when he was named OSRX Chief Formulation Officer.

“The success of OSRX has provided me with some wonderful career opportunities and the ability to expand my skillset,” says Holdorf. “It has all been serendipitous. I have a background in sterile production, and when OSRX was formed, one of the first priorities for Anthony Sampietro (Ocular Science CEO) was to convert our facility to allow us to perform sterile compounding.”

“The growth of OSRX has been fueled by people who care; we focus on treating all clients fairly. It starts with Anthony and permeates the entire company. We have excellent relationships with our accounts and employees and we’re continuously improving our operations at all levels. It comes down to hiring high-quality employees and investing in them.”

After receiving a Doctor of Pharmacy from the University of Montana in 2004, Holdorf worked as an inpatient clinical pharmacist (at a 200-bed level II hospital), a home infusion pharmacist and specialized in compounding intrathecal injections. He joined OSRX in 2019.

“Brian is an absolute wizard in terms of tailor-making and innovating compounded formulations – nobody does it better,” says Sampietro. “His precision and commitment to quality is a core reason we reached record-breaking revenue in 2022 and our national footprint continues to expand year after year. Brian is undoubtedly one of the leading pharmaceutical minds in the country.” 

Holdorf’s primary focus for OSRX in 2023 will be enhancing the organization to better align with Good Manufacturing Practice regulations and scaling OSRX processes to meet physician demand. He will also continue his specialized education by attending national conferences regarding quality improvement and the evolving pharmacy landscape. He is a member of the Controlled Environmental Testing Association and serves as a preceptor for fourth-year pharmacy students in collaboration with the University of Montana.

“I’ve worked with Brian for nine years and watched him create solutions for patients and providers time and time again. He has the ability to ‘think outside the box’ and apply scientific principles in unison, a rare talent,” says OSRX Chief Pharmacy Officer Amy Frost. “Brian has never faltered to put patient safety at the forefront of everything we do and the satisfaction of our customers is a testament to that quality. I’m excited that his dedication and industry expertise are being rewarded by this promotion, and look forward to more great things to come of Brian’s work.”

OSRX operates in full compliance with Section 503A regarding compounded drugs as defined in the FD&C Act.

*Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, and quality. 503A compounding pharmacies are not required to comply with cGMP requirements but can be inspected by FDA. References available upon request.

Click here to view potential contraindications.